Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks.
Robert J RolfeHassaan ShaikhL Gayani TillekeratnePublished in: Infectious diseases of poverty (2022)
Evidence shows that MDA-azithromycin programs may be beneficial for reducing trachoma, yaws, and mortality in children < 5 years of age in certain under-resourced settings. However, there are significant potential risks that need to be considered when deciding how, when, and where to implement these programs. Robust systems to monitor benefits as well as adverse effects and antibacterial resistance are warranted in communities where MDA-azithromycin programs are implemented.